BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18272323)

  • 1. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study.
    Wittorf A; Sickinger S; Wiedemann G; Klingberg S
    Arch Clin Neuropsychol; 2008 May; 23(3):271-82. PubMed ID: 18272323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia.
    Andersen R; Fagerlund B; Rasmussen H; Ebdrup BH; Aggernaes B; Gade A; Oranje B; Glenthoj B
    Psychiatry Res; 2011 May; 187(1-2):49-54. PubMed ID: 21075453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls.
    Ahn YM; Lee KY; Kim CE; Kim JJ; Kang DY; Jun TY; Choi JS; Chung IW; Kim SH; Hwang SS; Kim YS
    J Clin Psychopharmacol; 2009 Apr; 29(2):117-23. PubMed ID: 19512972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Social cognition and atypical antipsychotic agents in the treatment of persons with schizophrenia: preliminary data from a naturalistic study].
    Mazza M; Tozzini C; Giosué P; De Risio A; Palmucci M; Roncone R; Casacchia M
    Clin Ter; 2003; 154(2):79-83. PubMed ID: 12856365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia.
    Rémillard S; Pourcher E; Cohen H
    J Int Neuropsychol Soc; 2008 Jan; 14(1):110-8. PubMed ID: 18078537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study.
    Guo X; Zhai J; Wei Q; Twamley EW; Jin H; Fang M; Hu M; Zhao J;
    Neurosci Lett; 2011 Oct; 503(2):141-6. PubMed ID: 21888948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
    Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
    Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
    Kilian R; Angermeyer MC
    Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication.
    Snyder PJ; Jackson CE; Piskulic D; Olver J; Norman T; Maruff P
    Psychiatry Res; 2008 Sep; 160(3):316-26. PubMed ID: 18579217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Velligan DI; Miller AL
    J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
    Piskulić D; Olver JS; Maruff P; Norman TR
    Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up.
    Tabarés-Seisdedos R; Balanzá-Martínez V; Sánchez-Moreno J; Martinez-Aran A; Salazar-Fraile J; Selva-Vera G; Rubio C; Mata I; Gómez-Beneyto M; Vieta E
    J Affect Disord; 2008 Aug; 109(3):286-99. PubMed ID: 18289698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia.
    Kontis D; Theochari E; Kleisas S; Kalogerakou S; Andreopoulou A; Psaras R; Makris Y; Karouzos C; Tsaltas E
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1333-41. PubMed ID: 20691745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.
    Chen CK; Chen YC; Huang YS
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):17-22. PubMed ID: 19067997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
    Krivoy A; Weizman A; Laor L; Hellinger N; Zemishlany Z; Fischel T
    Eur Neuropsychopharmacol; 2008 Feb; 18(2):117-21. PubMed ID: 17728110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.